Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Intranasal Corticosteroids Are Associated With Better Outcomes in COVID-19
  2. Safety and Efficacy of the AZD1222 Vaccine
  3. Effectiveness of Moderna, Pfizer-BioNTech, and Janssen Vaccines in Preventing COVID-19 Hospitalizations in Adults
  4. Outcomes With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes
  5. Long-Term Symptoms Among Adults Infected With SARS-CoV-2
  6. Effectiveness of COVID-19 Vaccines in Ambulatory and Inpatient Care Settings
  7. Increased SARS-CoV-2 Antibody Response Following Vaccination With mRNA-1273
  8. Acute MI and Ischemic Stroke Risk After COVID-19 in Sweden
  9. Awake Prone Positioning for COVID-19 Respiratory Failure
  10. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

Most Read This Week

Recently Updated